Results 121 to 130 of about 46,312 (227)

Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

New England Journal of Medicine, 2009
S. Schulman, C. Kearon, A. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, David Baanstra, J. Schnee, S. Goldhaber   +8 more
semanticscholar   +1 more source

Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report

International Journal of Emergency Medicine
Dabigatran is an oral anticoagulant that is mainly renally excreted. Despite its efficacy in preventing thromboembolic events, concerns arise regarding bleeding complications in patients with acute kidney injury. Idarucizumab is its specific antidote and
Rafik Matbouli, Olivier Pantet, Julien Castioni, Nima Vakilzadeh, Lorenzo Alberio, Olivier Hugli   +5 more
doaj   +1 more source

Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? [PDF]

, 2014
Al-Khatib, SM, Banerjee, A, Blendea, D, Camm, AJ, Conroy, JM, Cosio, FG, De Bono, J, G Cosio, MD, Guasch, E, Halperin, JL, Hess, PL, Kirchhof, P, Lip, GY, Nattel, S, Ruskin, J, Savelieva, I   +15 more
core   +1 more source

Management of intracranial bleeding associated with dabigatran use in a neuroscience hospital [PDF]

, 2013
Dabigatran, an alternative to warfarin for prevention of stroke with non-valvular atrial fibrillation (AF), offers advantages of a fixed dosage, minimal laboratory monitoring and limited medication interactions.
Merli, MD, Geno J., Perez, MD, Alejandro, Thomson, Lynda   +2 more
core   +1 more source

Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation

New England Journal of Medicine, 2017
H. Calkins, S. Willems, E. Gerstenfeld, A. Verma, R. Schilling, S. Hohnloser, K. Okumura, H. Serota, M. Nordaby, K. Guiver, B. Biss, M. Brouwer, M. Grimaldi   +12 more
semanticscholar   +2 more sources

Advances in emerging therapies 2009 [PDF]

, 2010
Lees, K.R., McArthur, K.
core   +1 more source

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects

Circulation, 2011
E. Eerenberg, P. Kamphuisen, M. Sijpkens, J. Meijers, H. Buller, M. Levi   +5 more
semanticscholar   +1 more source

Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile

Cost Effectiveness and Resource Allocation
Background Atrial fibrillation (AF) is the most common sustained arrhythmia in adults, associated with significant morbidity, mortality, and economic burden due to thromboembolic events.
Tomás Abbot, Nicolás Armijo, Luis Rojas Orellana, Andrés Giglio Jiménez, Carlos Balmaceda, Manuel Espinoza   +5 more
doaj   +1 more source

Dabigatran outperforms warfarin in elderly patients with atrial fibrillation and stable coronary artery disease: reduced risks of bleeding and cardiovascular events. [PDF]

Am J Transl Res
Song L, Li N, Wang Z, Yu J, Qin J.
europepmc   +1 more source

The novel anticoagulant dabigatran versus enoxaparin for thromboprophylaxis following total hip replacement: a meta-analysis. [PDF]

BMC Cardiovasc Disord
Huang J, Ye J.
europepmc   +1 more source